High seroconversion rate and SARS-CoV-2 Delta neutralization in people with HIV vaccinated with BNT162b2.
Journal
AIDS (London, England)
ISSN: 1473-5571
Titre abrégé: AIDS
Pays: England
ID NLM: 8710219
Informations de publication
Date de publication:
01 09 2022
01 09 2022
Historique:
pubmed:
23
6
2022
medline:
20
8
2022
entrez:
22
6
2022
Statut:
ppublish
Résumé
To assess humoral responses to SARS-CoV-2 Delta-variant in people with HIV (PWH) after BNT162b2-vaccination. Multicenter cohort study of PWH with CD4 + cell count less than 500 cells/μl and viral load less than 50 copies/ml on stable antiretroviral therapy for at least 3 months. Anti-SARS-CoV-2 receptor-binding-domain IgG antibodies (anti-RBD IgG) were quantified and neutralization capacity was evaluated by ELISA/GenScript and virus-neutralization-test against the D614G-strain, beta and delta variants before vaccination (day 0) and 1 month after complete schedule (M1). We enrolled 97 PWH, 85 received two vaccine shots. The seroconversion rate for anti-RBD IgG was 97% [95% confidence interval (CI) 90-100%] at M1. Median (IQR) anti-RBD IgG titer was 0.97 (0.97-5.3) BAU/ml at D0 and 1219 (602-1929) at M1. Neutralization capacity improved between D0 (15%; 50% CI 8-23%) and M1 (94%; 95% CI 87-98%) ( P < 0.0001). At M1, NAbs against the D614G strain, beta and delta variants were present in 82, 77, and 84% PWH, respectively. The seroconversion rate and median anti-RBD-IgG level were 91% and 852 BAU/ml, respectively, in PWH with CD4 + cell count less than 250 ( n = 13) and 98% and 1270 BAU/ml for CD4 + greater than 250 ( n = 64) ( P = 0.3994). NAbs were present in 73% of PWH with CD4 + less than 250 and 97% of those with CD4 + cell count greater than 250 ( P = 0.0130). NAbs against beta variant were elicited in 50% in PWH with CD4 + cell count less than 250 and in 81% of those with CD4 + cell count greater than 250 ( P = 0.0292). CD4 + and CD8 + T-cell counts were unchanged, whereas CD19 + B-cell counts decreased after vaccination(208 ± 124 at D0 vs. 188 ± 112 at M1, P < 0.01). No notable adverse effects or COVID-19 cases were reported. Seroconversion rates were high, with delta-neutralization rates similar to those for the D61G strain, after a two-dose BNT162b2 vaccination in PWH.
Identifiants
pubmed: 35730380
doi: 10.1097/QAD.0000000000003300
pii: 00002030-202209010-00007
doi:
Substances chimiques
Antibodies, Viral
0
Immunoglobulin G
0
BNT162 Vaccine
N38TVC63NU
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1545-1552Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Références
Berenguer J, Diez C, Martin-Vicente M, Mican R, Perez-Elias MJ, Garcia-Fraile LJ, et al. Prevalence and factors associated with SARS-CoV-2 seropositivity in the Spanish HIV Research Network Cohort . Clin Microbiol Infect 2021; 27:1678–1684.
Lombardi F, Ricci R, Belmonti S, Fabbiani M, Borghetti A, Baldin G, et al. Seroprevalence of SARS-CoV-2 antibodies in HIV-infected PLWHIV in Rome, Italy during the COVID-19 Outbreak . Diagnostics (Basel) 2021; 11:1154.
Noe S, Schabaz F, Heldwein S, Mayer W, Ruecker K, Tiller FW, et al. ArcHIV study group. HIV and SARS-CoV-2 co-infection: cross-sectional findings from a German ’hotspot’ . Infection 2021; 49:313–320.
Spinelli MA, Lynch KL, Yun C, Glidden DV, Peluso MJ, Henrich TJ, et al. SARS-CoV-2 seroprevalence, and IgG concentration and pseudovirus neutralising antibody titres after infection, compared by HIV status: a matched case-control observational study . Lancet HIV 2021; 8:e334–e341.
Dong Y, Li Z, Ding S, Liu S, Tang Z, Jia L, et al. HIV infection and risk of COVID-19 mortality: a meta-analysis . Medicine (Baltimore) 2021; 100:e26573.
Sarkar S, Khanna P, Singh AK. Impact of COVID-19 in PLWHIV with concurrent co-infections: a systematic review and meta-analyses . J Med Virol 2021; 93:2385–2395.
Ssentongo P, Heilbrunn ES, Ssentongo AE, Advani S, Chinchilli VM, Nunez JJ, Du P. Epidemiology and outcomes of COVID-19 in HIV-infected individuals: a systematic review and meta-analysis . Sci Rep 2021; 11:6283.
Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, et al. BNT162b2 mRNA covid-19 vaccine in a nationwide mass vaccination setting . N Engl J Med 2021; 384:1412–1423.
Chagla Z. The BNT162b2 (BioNTech/Pfizer) vaccine had 95% efficacy against COVID-19 >/=7 days after the 2nd dose . Ann Intern Med 2021; 174:JC15.
Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. C4591001 Clinical Trial Group. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine . N Engl J Med 2020; 383:2603–2615.
Madhi SA, Koen AL, Izu A, Fairlie L, Cutland CL, Baillie V, et al. Wits VIDA COVID team. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial . Lancet HIV 2021; 8:e568–e580.
Polvere I, Parrella A, Casamassa G, D’Andrea S, Tizzano A, Cardinale G, et al. Seroprevalence of anti-SARS-CoV-2 IgG and IgM among adults over 65 years old in the south of Italy . Diagnostics (Basel) 2021; 11:483.
Garcia-Beltran WF, Lam EC, St Denis K, Nitido AD, Garcia ZH, Hauser BM, et al. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity . Cell 2021; 184:2372.e9–2383.e9.
Marot S, Malet I, Leducq V, Abdi B, Teyssou E, Soulie C, et al. Neutralization heterogeneity of United Kingdom and South-African SARS-CoV-2 variants in BNT162b2-vaccinated or convalescent COVID-19 healthcare workers . Clin Infect Dis 2022; 74:707–710.
Planas D, Bruel T, Grzelak L, Guivel-Benhassine F, Staropoli I, Porrot F, et al. Sensitivity of infectious SARS-CoV-2 B.1.1. 7 and B. 1. 351 variants to neutralizing antibodies . Nat Med 2021; 27:917–924.
Planas D, Veyer D, Baidaliuk A, Staropoli I, Guivel-Benhassine F, Rajah MM, et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization . Nature 2021; 596:276–280.
von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies . J Clin Epidemiol 2008; 61:344–349.
Tan CW, Chia WN, Qin X, Liu P, Chen MI, Tiu C, et al. A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction . Nat Biotechnol 2020; 38:1073–1078.
Marot S, Malet I, Leducq V, Zafilaza K, Sterlin D, Planas D, et al. Rapid decline of neutralizing antibodies against SARS-CoV-2 among infected healthcare workers . Nat Commun 2021; 12:844.
Xie X, Zou J, Fontes-Garfias CR, Xia H, Swanson KA, Cutler M, et al. Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera . bioRxiv 2021.
Fu Y, Chen F, Cui L, Zhao Y, Zhang H, Fu S, et al. Immunological analysis of people in Northeast China after SARS-CoV-2 inactivated vaccine injection . Vaccines (Basel) 2021; 9:1028.
Levy I, Wieder-Finesod A, Litchevsky V, Biber A, Indenbaum V, Olmer L, et al. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in people living with HIV-1 . Clin Microbiol Infect 2021; 27:1851–1855.
Frater J, Ewer KJ, Ogbe A, Pace M, Adele S, Adland E, et al. Oxford COVID Vaccine Trial Group. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial . Lancet HIV 2021; 8:e474–e485.
Woldemeskel BA, Karaba AH, Garliss CC, Beck EJ, Wang KH, Laeyendecker O, et al. The BNT162b2 mRNA vaccine elicits robust humoral and cellular immune responses in people living with HIV . Clin Infect Dis 2021.
Noe S, Ochana N, Wiese C, Schabaz F, Von Krosigk A, Heldwein S, et al. Humoral response to SARS-CoV-2 vaccines in people living with HIV . Infection 2021; 50:617–623.
Antinori A, Cicalini S, Meschi S, et al . Immunogenicity of mRNA vaccination against SARS-CoV-2 in persons living with HIV (PLWHs) with low CD4 count or previous AIDS . 18th European AIDS Conference, EACS 2021 , October 27–30, 2021, London. Abstract OS4/3.
Tuan JJ, Zapata H, Critch-Gilfillan T, Ryall L, Turcotte B, Mutic S, et al. Qualitative assessment of anti-SARS-CoV-2 spike protein immunogenicity (QUASI) after COVID-19 vaccination in older people living with HIV . HIV Med 2021; 23:178–185.
Anna F, Goyard S, Lalanne AI, Nevo F, Gransagne M, Souque P, et al. High seroprevalence but short-lived immune response to SARS-CoV-2 infection in Paris . Eur J Immunol 2021; 51:180–190.
Carrat F, de Lamballerie X, Rahib D, Blanche H, Lapidus N, Artaud F, et al. or the SAPRIS and SAPRIS-SERO study groups. Antibody status and cumulative incidence of SARS-CoV-2 infection among adults in three regions of France following the first lockdown and associated risk factors: a multicohort study . Int J Epidemiol 2021; 50:1458–1472.